Related Experiment Video

Updated: Aug 12, 2026

A11-positive β-amyloid Oligomer Preparation and Assessment Using Dot Blotting Analysis
06:17

A11-positive β-amyloid Oligomer Preparation and Assessment Using Dot Blotting Analysis

Published on: May 22, 2018

Inhibition of beta-amyloid cytotoxicity by midkine

G S Yu1, J Hu, H Nakagawa

  • 1R & D Center, BML, Kawagoe City, Saitama, Japan.

Neuroscience Letters
|April 24, 1999
PubMed

Insights

Midkine (MK) protein interacts with amyloid-beta (Abeta) to form complexes, inhibiting Abeta aggregation and cell death. This suggests MK may protect against Alzheimer

Area of Science:

  • Neuroscience
  • Molecular Biology
  • Biochemistry

Background:

  • Midkine (MK) is a growth factor primarily expressed during fetal development.
  • MK has been detected in the senile plaques characteristic of Alzheimer's disease (AD).
  • The role of MK in the pathogenesis of AD, particularly in amyloid plaque formation, remains unclear.

Purpose of the Study:

  • To investigate the in vitro effect of Midkine (MK) on amyloid-beta (Abeta) aggregation.
  • To determine if MK influences Abeta-induced cytotoxicity.
  • To elucidate the potential protective role of MK in Alzheimer's disease pathology.

Main Methods:

  • In vitro incubation of MK with Abeta peptides.
  • Analysis of MK/Abeta complex formation.
  • Assessment of Abeta self-aggregation inhibition by MK.
  • Evaluation of MK's effect on Abeta-induced cytotoxicity in PC12h cells.

Main Results:

  • MK incubation with Abeta led to the formation of stable MK/Abeta complexes.
  • The C-terminus of MK (amino acids 60-121) was sufficient for complex formation.
  • MK significantly inhibited the self-aggregation of Abeta.
  • MK demonstrated a protective effect against Abeta-induced cytotoxicity in neuronal cells.

Conclusions:

  • Midkine (MK) directly interacts with amyloid-beta (Abeta), forming complexes that inhibit Abeta aggregation.
  • MK protects neuronal cells from Abeta-induced toxicity, suggesting a neuroprotective role in Alzheimer's disease.
  • The findings imply that MK expression may be a compensatory mechanism to prevent cell death in AD.

More Related Videos

Chemical Inactivation of the E3 Ubiquitin Ligase Cereblon by Pomalidomide-based Homo-PROTACs10:44

Chemical Inactivation of the E3 Ubiquitin Ligase Cereblon by Pomalidomide-based Homo-PROTACs

Published on: May 15, 2019

Mechanism of Kemeng Fang's Inhibition of Podocyte Apoptosis in Rats with Membranous Nephropathy through the PI3K/AKT Signaling Pathway07:15

Mechanism of Kemeng Fang's Inhibition of Podocyte Apoptosis in Rats with Membranous Nephropathy through the PI3K/AKT Signaling Pathway

Published on: August 23, 2024

Related Concept Videos

Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
Drugs that Destabilize Microtubules01:10

Drugs that Destabilize Microtubules

Microtubules are dynamic structures and can be regulated by microtubule targeting agents (MTAs). Microtubule destabilizing drugs are a class of MTAs that destabilize and prevent microtubules' polymerization. Both natural and synthetic chemicals can be found under this class of drugs. Vincristine and vinblastine, two vinca alkaloids, and colchicine were among the first to be discovered. These drugs can affect cells in various ways, either by inducing a change in cell morphology, preventing...
Inhibition of CDK Activity02:34

Inhibition of CDK Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
Antifungal Agents01:15

Antifungal Agents

Amphotericin B is a broad-spectrum antifungal agent that exploits structural differences between fungal and mammalian cell membranes. Its amphipathic structure—featuring a hydrophobic polyene-lactone ring and a hydrophilic region containing mycosamine and carboxylic acid groups—enables selective binding to ergosterol, a sterol predominantly found in fungal plasma membranes. This selective interaction underlies the drug’s antifungal activity, although weak binding to cholesterol contributes to...